LON:RENE ReNeuron Group (RENE) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ReNeuron Group Stock (LON:RENE) Get ReNeuron Group alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume177,373 shsAverage Volume578,249 shsMarket Capitalization£1.93 millionP/E RatioN/ADividend Yield0.76%Price TargetN/AConsensus RatingN/A Company Overview ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom. Read More Receive RENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReNeuron Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENE Stock News HeadlinesTRADING UPDATES: PetroTal buys Peru's Block 131 for USD5.0 millionMay 17, 2024 | lse.co.ukReNeuron CFO steps down to pursue other opportunitiesApril 17, 2024 | lse.co.ukALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.June 3 at 1:00 AM | Weiss Ratings (Ad)Medtech firm IQ Endoscopes plans to create 100 new jobs and raise millionsApril 2, 2024 | msn.comUpland Resources shares soar as company prepares for Sarawak drillingMarch 28, 2024 | lse.co.ukCompany given millions of public money in Welsh Gov's disastrous foray into biotech investments collapses into administrationMarch 22, 2024 | msn.comTRADING UPDATES: ReNeuron appoints administrators as rescue talks failMarch 20, 2024 | lse.co.ukReNeuron Group PLC RENEFebruary 21, 2024 | morningstar.comMSee More Headlines RENE Stock Analysis - Frequently Asked Questions How were ReNeuron Group's earnings last quarter? ReNeuron Group plc (LON:RENE) announced its earnings results on Monday, July, 20th. The company reported ($35.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($50.20) by $14.30. How do I buy shares of ReNeuron Group? Shares of RENE stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that ReNeuron Group investors own include 10094 (IRD.TO) (IRD), Sareum (SAR), ValiRx (VAL), IOG (IOG), Dignity (DTY), Tri-Star Resources plc (TSTR.L) (TSTR) and Company Calendar Last Earnings7/20/2020Today6/03/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolLON:RENE CIKN/A Webwww.reneuron.com Phone+44-20-38198400FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.07 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.77% Return on Assets-37.91% Debt Debt-to-Equity Ratio14.25 Current Ratio1.51 Quick Ratio2.02 Sales & Book Value Annual Sales£783 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.61 Book ValueGBX 4 per share Price / BookN/AMiscellaneous Outstanding Shares57,170,000Free FloatN/AMarket Cap£1.93 million OptionableNot Optionable Beta0.83 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (LON:RENE) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReNeuron Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ReNeuron Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
